Download PDF
Thromb Haemost 1986; 56(01): 040-044
DOI: 10.1055/s-0038-1661599
Original Article
Schattauer GmbH Stuttgart

Inhibition of PAF-lnduced Systemic Responses in the Rat, Guinea Pig, Dog and Primate by the Receptor Antagonist SRI 63-441

D A Handley
The Platelet Department, Sandoz Research Institute, East Hanover, NJ, USA
,
J C Tomesch
The Platelet Department, Sandoz Research Institute, East Hanover, NJ, USA
,
R N Saunders
The Platelet Department, Sandoz Research Institute, East Hanover, NJ, USA
› Author Affiliations
Further Information

Publication History

Received 14 January 1986

Accepted 23 April 1986

Publication Date:
13 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Systemic administration of synthetic PAF produces a number of dose-dependent circulatory effects in a variety of species. We have evaluated a novel PAF antagonist, SRI 63-441, for its ability to inhibit PAF-induced effects in the rat, guinea pig, dog and primate. In the rat, a 100 ng kg-1 i.v. PAF challenge produced a (mean ± 1 S.D.) 39 ± 5% decrease in carotid blood pressure. Prior injection of SRI 63-441 inhibited this hypotensive response in a dose-dependent manner, with an ED50 of 0.15 mg kg-1 i.v. In the guinea pig, PAF at 100 ng kg-1 elicited a 50 ± 8% increase in hematocrit and a 50 ± 11% elevation in bronchial resistance. The ED50 values for inhibition by SRI 63-441 of these two physiological parameters were 0.012 mg kg-1 and 0.035 mg kg-1 i.a., respectively. Dogs challenged with 1.5 μg kg-1 PAF i.v. exhibited 28.7 ±6.5% increase in hematocrit 10 min after injection. The ED50 value for SRI 63-441 inhibition of hemoconcentration in the dog was 0.18 mg kg-1 i.v. In the primate model of PAF-induced hemoconcentration, controls responded to 3.5 pg kg-1 i.v. PAF with a 30 ± 6% increase in hematocrit. Using the primates in a cross-over design, the ED50 OF SRI 63-441 WAS 0.11 MG KG 1 i.v. At this ED50 value, the ratio of nmol kg-1 PAF used versus nmol kg-1 antagonist is ∼1:25. The effectiveness of SRI 63-441 in these models suggest potential clinical applications in disease states involving hyperpermeability and pulmonary dysfunction.

Keywords

Platelet - activating factor - Guinea pig - Rat - Dog - Primate - Hemoconcentration - Vascular permeability - Receptor antagonist
 

  • References

  • 1 McManus LM, Pinckard RN, Fitzpatrick FA, O’Rourke RA, Crawford MH, Hanahan DJ. Acetyl glyceryl ether phosphoryl-choline. Intravascular alterations following intravenous infusion into the baboon. Lab Invest 1981; 45: 303-309
    PubMedGoogle Scholar
  • 2 Wedmore CV, Williams TJ. Platelet-activating factor (PAF), a secretory product of polymorphonuclear leukocytes, increases vascular permeability in rabbit skin. Br J Pharmacol 1981; 74: 916-919
    PubMedGoogle Scholar
  • 3 Handley DA, Arbeeny CM, Lee ML, Van Valen RG, Saunders RN. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology 1984; 8: 137-142
    CrossrefPubMedGoogle Scholar
  • 4 Handley DA, Lee ML, Saunders RN. Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemocon-centration in the guinea pig. Thromb Haemostas 1985; 54: 756-759
    PubMedGoogle Scholar
  • 5 Handley DA, Van Valen RG, Melden MK, Saunders RN. Evaluation of dose and route effects of platelet activating factor-induced extravasation in the guinea pig. Thromb Haemostas 1984; 52: 34-36
    PubMedGoogle Scholar
  • 6 Tanaka S, Kasuya Y, Masuda Y, Shigenobu K. Studies of the hypotensive effects of platelet activating factor (PAF, 1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits and dogs. J Pharm Dyn 1983; 6: 866-874
    CrossrefPubMedGoogle Scholar
  • 7 Blank ML, Synder F, Byers LW, Brooks B, Muirhead EE. Antihypertensive activity of an alkyl ether analogue of phosphoryl-choline. Biochem Biophys Res Comm 1979; 90: 1194-1200
    CrossrefPubMedGoogle Scholar
  • 8 Muirhead EE, Byers LW, Desiderio D, Smith KA, Prewitt RL, Brooks B. Alkyl ether analogs of phosphatidylcholine are orally active in hypertensive rabbits. Hyperten 1981; 3: 107-113
    CrossrefPubMedGoogle Scholar
  • 9 Patterson R, Harris KE. The activity of aerosolized and intracutane-ous synthetic platelet-activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. J Lab Clin Med 1983; 102: 933-938
    PubMedGoogle Scholar
  • 10 Vargaftig BB, Lefort J, Chignard M, Benveniste J. Platelet-activating factor induces platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol 1980; 65: 185-189
    CrossrefPubMedGoogle Scholar
  • 11 Denjean A, Arnoux B, Masse R, Lockhart A, Benveniste J. Acute effects of intratracheal administration of platelet-activating factor in baboons. J Appl Physiol 1983; 55: 799-804
    CrossrefPubMedGoogle Scholar
  • 12 Ezra D, Feuerstein G, Ramwell PW, Hayes E, Goldstein RE. Effects of platelet-activating factor on coronary hemodynamics and coronary venous plasma levels of TXB2, 6-keto-PGF1α and leukotriene C4 immunoreactivity in the intact domestic pig heart. Adv Prostaglandin Thromboxane Res 1985; 13: 19-21
    PubMedGoogle Scholar
  • 13 Feuerstein G, Boyd LM, Ezra D, Goldstein RE. Effect of platelet-activating factor on coronary circulation of the domestic pig. Am J Physiol 1984; 246: H466-H471
    PubMedGoogle Scholar
  • 14 Levi R, Burke JA, Guo Z-G, Hattori Y, Hoppens CM, McManus LM, Hanahan DJ, Pinckard RN. Acetyl glyceryl ether phosphoryl-choline (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. Circ Res 1984; 54: 117-124
    CrossrefPubMedGoogle Scholar
  • 15 Terashita Z, Imura Y, Nishikawa K, Sumida S. Is platelet activating factor (PAF) a mediator of endotoxin shock?. Eur J Pharmacol 1985; 109: 257-263
    CrossrefPubMedGoogle Scholar
  • 16 Pinckard RN. Platelet-activating factor. Hospit Pract 1983; 70: 67-76
    PubMedGoogle Scholar
  • 17 Stimler NP, Bloor CM, Hugli TE, Wykle RL, McCall CE, O’Flaherty JT. Anaphylactic actions of platelet-activating factor. Am J Pathol 1981; 105: 64-73
    PubMedGoogle Scholar
  • 18 Valone FH. Isolation of a platelet membrane protein which binds the platelet-activating factor 1-0-hexadecy1-2-acetyl-sn-glycero-3-phos-phorylcholine. Immunology 1984; 52: 169-174
    PubMedGoogle Scholar
  • 19 Shaw JO, Pinckard RN, Ferrigni KS, McManus LM, Hanahan DJ. Activation of human neutrophils with 1-0 hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor). J Immunol 1981; 127: 1250-1261
    CrossrefPubMedGoogle Scholar
  • 20 Stimler NP, O’Flaherty JT. Spasmogenic properties of platelet-activating factor. Evidence for a direct mechanism in the contractile response of pulmonary tissues. Am J Pathol 1983; 113: 75-83
    PubMedGoogle Scholar
  • 21 Apprill P, Schmitz J, Campbell W, Buja LM, Ashton J, Willerson J. Platelet activating factor causes cyclic flow variations despite thromboxane synthetase inhibition and pharmacologic antagonism of alpha2 adrenergic receptors and serotonin receptors. Fed Proc 1984; 43: 51
    PubMedGoogle Scholar
  • 22 Kamitani T, Katamoto M, Tatsumi M, Katsata K, Ono T, Kikuchi H, Kumada S. Mechanism(s) of the hypotensive effect of synthetic 1-0-octadecyl-2-0-acetyl-glycero-3-phosphorylcholine. Eur J Pharmacol 1984; 98: 357-364
    CrossrefPubMedGoogle Scholar
  • 23 Terashita Z, Taushima S, Yoshioka Y, Nomura H, Inada Y, Nishikawa K. CV-3988 - A specific antagonist of platelet-activating factor (PAF). Life Sci 1983; 32: 1975-1981
    CrossrefPubMedGoogle Scholar
  • 24 Sanches-Crespo M, Fernandes-Gallardo S, Nieto ML, Baranes J, Barquet P. (1985) Inhibition of the vascular actions of immunoglobulin G aggregates by BN 52021, a highly specific antagonist of PAF-acether. Immunopharmacology 1985; 10: 69-75
    CrossrefPubMedGoogle Scholar
  • 25 Hwang S-B, Li C-H, Lam M-H, Shen TY. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist. Lab Invest 1985; 52: 617-630
    PubMedGoogle Scholar
  • 26 Camussi G, Tetta D, Deregibus M, Bussolino F, Vercellone A. Platelet activating factor (paf-acether) in experimentally-induced rabbit acute sickness. Role of basophil-derived paf-acether in immune complex deposition. J Immunol 1982; 128: 86
    PubMedGoogle Scholar
  • 27 Handley DA, Van Valen RG, Melden MK, Flury S, Lee ML, Saunders RN. Inhibition and reversal of endotoxin-, aggregated IgG-and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist. Immunopharmacology 1986 (in press)
    PubMedGoogle Scholar
  • 28 Handley DA, Farley C, Deacon RW, Saunders RN. Evidence for distinct systemic extravasation effects of platelet activating factor, leukotrienes B4, C4, D4 and histamine in the guinea pig. Prostaglandins Leukotrienes Med 1986; 21: 269-277
    CrossrefPubMedGoogle Scholar
  • 29 Handley DA, Van Valen RG, Saunders RN. Vascular responses of platelet activating factor in the cebus apella primate and inhibitory profiles of antagonists SRI 63-072 and SRI 63-119. Immunopharmacology 1986 (in press)
    PubMedGoogle Scholar
  • 30 Lefort J, Wal F, Chignard M, Medeiros MC, Vargaftig BB. Pharmacological properties of PAF-acether in guinea pigs: Platelet dependent and independent reactions. Agents Actions 1982; 12: 723-725
    CrossrefPubMedGoogle Scholar
  • 31 Lellouch-Tubiana A, Lefort J, Pirotzky E, Vargaftig BB, Pfister A. Ultrastructural evidence for extravascular platelet recruitment in the lung upon intravenous injection of platelet activating factor (PAF-acether) to guinea pigs. Br J Path 1985; 66: 345-352
    PubMedGoogle Scholar
  • 32 Lewis AJ, Dervinis A, Chang J. The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation. Agents Actions 1984; 15: 636-640
    CrossrefPubMedGoogle Scholar
  • 33 Vargaftig BB, Lefort J, Chignard M, Benveniste J. Platelet-activating factor induces platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol 1980; 65: 185-193
    CrossrefPubMedGoogle Scholar
  • 34 Bessin P, Bonnet J, Apffel D, Soulard C, Desgroux L, Pelas I, Benveniste J. Acute circulation collapse caused by platelet-activating factor (paf-acether) in dogs. Eur J Pharmacol 1983; 86: 403-413
    CrossrefPubMedGoogle Scholar
  • 35 Shen TY, Hwang SB, Chang MN, Doebber W, Lam M HT, Wu MS, Wang X, Han GQ, Li RZ. Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokad-sura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. Proc Natl Acad Sci USA 1985; 82: 672-676
    CrossrefPubMedGoogle Scholar
  • 36 Kornecki E, Ehrlich YM, Lemox RW. Platelet-activating factor induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. Science 1984; 226: 1954-1957
    PubMedGoogle Scholar
  • 37 Kasuya Y, Masuda Y, Shigenobu K. Possible role of endothelium in the vasodilator response of rat thoracic aorta to platelet activating factor (PAF). J Pharm Dyn 1984; 7: 138-147
    CrossrefPubMedGoogle Scholar
  • 38 Jackson CV, Driscoll EM, Pope TK, Lucchesi BR. PAF in platelet-mediated coronary artery vasodilation. Fed Proc 1985; 72: 190
    PubMedGoogle Scholar
  • 39 Feuerstein G, Lux WE, Snyder F, Ezra D, Faden AI. Hypotension produced by platelet-activating factor is reversed by thyrotropin-releasing hormone. Circ Shock 1984; 13: 255-260
    PubMedGoogle Scholar
  • 40 Humphrey DM, McManus LM, Hanahan DJ, Pinckard RN. Morphological basis of increased vascular permeability induced by acetyl glyceryl ether phosphorycoline. Lab Invest 1984; 50: 16-24
    PubMedGoogle Scholar
  • 41 Handley DA, Saunders RN. Involvement of platelet activating factor and inflammation in atherosclerosis. Drug Devel Res 1986; 7: 361-375
    CrossrefPubMedGoogle Scholar